Ratings Suven Pharmaceuticals Limited Bombay S.E.

Equities

SUVENPHAR

INE03QK01018

Delayed Bombay S.E. Other stock markets 01:02:02 13/05/2024 pm IST			5-day change	1st Jan Change
647.5 ^INR	+0.65%		-2.34%	-10.83%

27/03	Suven Pharmaceuticals Limited Announces Shifting of Registered Office	CI
05/03	Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
With an expected P/E ratio at 40.24 and 48.97 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SUVEN PHARMACEUTICALS LIMITED	-10.83%	1.96B	D-
ELI LILLY AND COMPANY	+30.38%	684B	C+
NOVO NORDISK A/S	+29.16%	568B	B
JOHNSON & JOHNSON	-4.36%	361B	C+
MERCK & CO., INC.	+19.30%	329B	B-
ABBVIE INC.	+3.73%	284B	C+
ASTRAZENECA PLC	+16.81%	240B	B+
NOVARTIS AG	+9.11%	208B	B-
ROCHE HOLDING AG	-7.77%	200B	A+
AMGEN INC.	+7.68%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes